Yahoo Italia Ricerca nel Web

  1. Annuncio

    relativo a: Steve Gillis
  2. Find Info You May Not See Elsewhere With Peoplelooker®. Easy Online Background Reports. We Found Steve Gillis's Public Records, Phone, Address, Social Media & More.

Risultati di ricerca

  1. Steve Gillis, Ph.D. Managing Director. Paul Berns. Managing Director. Clinton Bybee. Co-founder & Managing Director, Emeritus. Mark McDonnell. Managing Director, CFO & CAO. Jason Doren. General Counsel. Brian Cuneo. Senior Partner. John Maraganore, Ph.D. Venture Partner. George Scangos, Ph.D. Venture Partner. Jami Rubin. Venture Partner.

  2. He is focused on the evaluation of new life science technologies and on the development and growth of ARCH’s biotechnology portfolio companies. He is a director of 48 Bio, Pheast Therapeutics, beBio, SonoThera, Dispatch Bio, and Carrick Therapeutics.

  3. 7 giu 2023 · “We are pleased to partner with Bitterroot Bio as they work to bring groundbreaking medicines to patients with cardiovascular diseases,” said Dr. Steve Gillis, Chairman of the Board and...

  4. “We are pleased to partner with Bitterroot Bio as they work to bring groundbreaking medicines to patients with cardiovascular diseases,” said Dr. Steve Gillis, Chairman of the Board and managing director at ARCH Venture Partners.

  5. 7 giu 2023 · “We are pleased to partner with Bitterroot Bio as they work to bring groundbreaking medicines to patients with cardiovascular diseases,” said Dr. Steve Gillis, Chairman of the Board and...

  6. Board Chairman. Dr. Steve Gillis joined ARCH as a Venture Partner in 2005 and became a Managing Director in 2006. Dr. Gillis is focused on the evaluation of new life science technologies and the development and growth of ARCH’s biotechnology portfolio companies. He is a Director at Homology Medicines (FIXX) and Carrick Therapeutics and serves ...

  7. Gillis is focused on the evaluation of new life science technologies and also on the development and growth of ARCH’s biotechnology portfolio companies. He is a director of Accelerator, Allozyne, Variation Biotechnologies, Surface Logix, PhaseRx, Pulmatrix, and Qwell Pharmaceuticals.

  1. Annuncio

    relativo a: Steve Gillis